-
1مراجعة
المساهمون: Molecular and Integrative Biosciences Research Programme, Functional Lipidomics Group, Medicum, Biosciences, Department of Anatomy, Faculty of Medicine, University of Helsinki
مصطلحات موضوعية: Angiopoietin-like 3, Lipoprotein lipase, Lipid metabolism, Intracellular function, Hepatic lipids, Therapy target, FAMILIAL COMBINED HYPOLIPIDEMIA, LOW-DENSITY LIPOPROTEIN, PRORESOLVING LIPID MEDIATORS, FATTY LIVER, ANGPTL3 DEFICIENCY, ADIPOSE-TISSUE, PLASMA-LIPIDS, METABOLISM, HYPOBETALIPOPROTEINEMIA, GENE, 3111 Biomedicine, 1182 Biochemistry, cell and molecular biology
وصف الملف: application/pdf
العلاقة: The work in the authors' group is supported by the Novo Nordisk Foundation (VMO), the Paavo Nurmi Foundation (VMO), the Liv och Halsa Foundation (VMO), the Finnish Foundation for Cardiovascular Research (MJ, VMO), the Jane and Aatos Erkko Foundation (MJ), and the Magnus Ehrnrooth Foundation (ML, VMO).; Ruhanen , H , Haridas , P A N , Jauhiainen , M & Olkkonen , V M 2020 , ' Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions ' , Biochimica and Biophysica Acta. Molecular and Cell Biology of Lipids , vol. 1865 , no. 12 , 158791 . https://doi.org/10.1016/j.bbalip.2020.158791Test; d71df60d-8717-4504-b975-db16547614aa; http://hdl.handle.net/10138/333374Test; 000580571800001
-
2مراجعة
المؤلفون: Olkkonen, Vesa M., Sinisalo, Juha, Jauhiainen, Matti
المساهمون: Medicum, Department of Anatomy, University of Helsinki, Clinicum, Department of Medicine, Kardiologian yksikkö
مصطلحات موضوعية: Biomedicine, General medicine, internal medicine and other clinical medicine, ANGPTL3, Antibody therapy, apoC-III, ASO, CVD, TRL, CORONARY EVENTS, ANGIOPOIETIN-LIKE PROTEINS, OF-FUNCTION MUTATIONS, LOW-DENSITY LIPOPROTEINS, METABOLISM, ENDOTHELIAL-CELLS, B GENE, APOLIPOPROTEIN-C-III, FAMILIAL COMBINED HYPOLIPIDEMIA, PLASMA TRIGLYCERIDES
وصف الملف: application/pdf
العلاقة: Olkkonen , V M , Sinisalo , J & Jauhiainen , M 2018 , ' New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk? ' , Atherosclerosis , vol. 272 , pp. 27-32 . https://doi.org/10.1016/j.atherosclerosis.2018.03.019Test; RIS: urn:DCB2E061B965801A88654AD7BD00E58B; ORCID: /0000-0002-0169-5137/work/44999315; http://hdl.handle.net/10138/301989Test; bbc228ac-bd90-4baf-9445-6175e2dcae5b; 85043476678; 000430383800005
